ETST

Earth Science Tech, Inc.
1 filings tracked
healthcarepharmaceuticalsSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

The investment narrative has shifted from a speculative holding company to a strategic play on vertical integration.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Critics argue that the perceived margin expansion is a mirage, noting that cost of goods sold grew faster than revenue in the most recent period.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every ETST filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Earth Science Tech is attempting a high-stakes transition from a fragmented holding company to a vertically integrated healthcare platform.…

Latest Available Quarter (Q2 '26 (10-K))

Core Takeaway

The company is successfully scaling its integrated healthcare model but is running low on cash to sustain the pace.

Investor Lens

The trade-off is between a high-growth, high-margin business model and a precarious balance sheet.

Watch Next

Quarterly cash flow trends and any changes to FDA compounding regulations.

Calculated Financial Trajectory (Click to filter signals)

Revenue (M)35.7
FY '26: 35.7
Net Income (M)1.1
FY '26: 1.1
Gross Margin (%)71.0
FY '26: 71.0
Net Debt (M)0.9
FY '26: 0.9

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.23Q2 '26 (10-K)

Signal Timeline

bearishJun 18

Gross margins slipped from 73% to 71% as cost of goods sold grew faster than revenue.

margin compression
40%
bullishJun 18

Company is actively reducing share count through a $10M buyback program.

buyback
60%
bullishJun 18

Company successfully retired all long-term debt as of March 31, 2026.

debt restructure
50%

Filing History

10-KJun 18, 2026
Expand Sequence

The 10-K filing presents a company at a crossroads between aggressive growth and financial fragility. While ETST has successfully scaled its revenue and cleaned up its equity structure, the disconnect between reported net income and actual cash generation is stark. The company is betting heavily on the 'wellness-to-pharmacy' pipeline to drive a valuation re-rating, but this is countered by a shrinking cash pile and a high-risk regulatory environment. Investors are left to weigh the potential of a vertically integrated healthcare monopoly against the very real possibility of a liquidity event. The company's ability to navigate the transition from a penny-stock profile to a sustainable healthcare platform depends on whether it can convert its high gross margins into sustainable free cash flow before its current reserves are exhausted by operational burn and buyback obligations.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.